Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Vandana Singh Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their ...

I hope to see you there. Analyst’s Disclosure: I/we have a beneficial long position in the shares of RHHBY either through stock ownership, options, or other derivatives. I wrote this article ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received ... Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price ...

Poseida Therapeutics (PSTX) will cease trading on Nasdaq after the merger and will become a wholly owned subsidiary of Roche (OTCQX:RHHBY). PSTX stock price traded marginally higher, up 0.42% to $ ...

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...

CVS Health (NYSE:CVS) has submitted a letter to HHS Secretary Alex Azar emphasizing its support for the Administration's goal of lowering drug prices. It says its PBM ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock gained another 1.8% in after-hours trading. HALO also maintained its full-year ...